Evaluation of efficiency and sensitivity of 1D and 2D sample

pooling strategies for SARS-CoV-2 RT-qPCR screening purposes

Running title: *Evaluation of SARS-CoV-2 RT-qPCR pooling*

Jasper Verwilt[1,2,3], Jan Hellemans[4], Tom Sante[2,3], Pieter Mestdagh[1,2,3,4], Jo

Vandesompele[1,2,3,4]

1 OncoRNALab, Cancer Research Institute Ghent, Corneel Heymanslaan 10, 9000

Ghent, Belgium

2 Department of Biomolecular Medicine, Ghent University, Corneel Heymanslaan 10,

9000 Ghent, Belgium

3 Center for Medical Genetics, Ghent University, Corneel Heymanslaan 10, 9000

Ghent, Belgium

4 Biogazelle, Technologiepark 82, 9052 Zwijnaarde, Belgium

• 17 text pages

• 4 figures

Corr. author:

Jo Vandesompele

Corneel Heymanslaan 10, 9000 Gent, Belgium

+32 9 332 55 32

jo.vandesompele@ugent.be

Funding: UGent BOF-GOA LNCCA (BOF16/GOA/023, J.Va.)

Abstract

To increase the throughput, lower the cost, and save scarce test reagents, laboratories can pool patient samples before SARS-CoV-2 RT-qPCR testing. While different sample pooling methods have been proposed and effectively implemented in some laboratories, no systematic and large-scale evaluations exist using real-life quantitative data gathered throughout the different epidemiological stages. Here, we use anonymous data from 9673 positive cases to simulate and compare 1D and 2D pooling strategies. We show that the optimal choice of pooling method and pool size is an intricate decision with a testing population-dependent efficiency-sensitivity trade-off and present an online tool to provide the reader with custom real-time pooling strategy recommendations.

Introduction

One of the key strategies in the global battle against the COVID-19 pandemic is massive population testing. However, an ongoing shortage of time, reagents and testing capacity has tempered these efforts. Pooled testing of samples presents itself as a valid strategy to overcome these hurdles and to realize rapid, large-scale testing at lower cost and lower dependence on test reagents.

Multiple recent studies discussed pooling strategies in the frame of SARS-CoV-2 testing. Researchers have explored many strategies, but two of them have been welcomed for their simplicity and effectiveness: one-time pooling (1D pooling) and two-dimensional pooling (2D pooling). In 1D pooling, the samples are pooled, pools are tested and samples in positive pools are tested individually (Figure 1)[1–4]. Labs worldwide have extensively evaluated 1D pooling strategies for SARS-CoV-2 testing in the lab[5–8] or using simulations[1]. In 2D pooling, samples are organized in a 2D matrix and pools are created along the matrix's rows and columns. The pools are tested, and negative rows and columns are excluded from the matrix. Next, all remaining samples are tested individually (Figure 1)[9]. Other more complex strategies exist, such as repeated pooling[1], P-BEST[10] and Tapestry[11].

While attractive, pooling strategies come with inherent limitations. First, pooling dilutes each sample, possibly to such an extent that the viral RNA becomes undetectable, which results in false negative observations[8,9,12]. A second limitation is that an increase in sample manipulations augments the risk of cross-contamination and sample mix-ups, possibly leading to false negatives and false positives[9]. Last, when pooling, identifying individual positive samples will take an additional RNA

extraction and RT-qPCR run, while one run is sufficient when testing individual

samples without pooling.

Although the number of preprints and peer-reviewed publications on pooling

strategies for COVID-19 RT-qPCR-based testing has accelerated rapidly throughout

the pandemic, some critical aspects remain mostly ignored. First of all, the proposed

optimal pooling strategy is most often based on a binary classification of samples as

either positive or negative. This Boolean approach is not true to the real-world

situation and does not investigate the pooling step's dilution effect. Second, when

using Cq values as a semi-quantitative measure[13] of the viral loads, their overall

distribution should reflect the real-life population. A high fraction of Cq values close to

the limit of detection of the RT-qPCR assay produces an elevated risk of resulting in

false negative samples[14]. Last, since the Cq distribution of the sample population and

prevalence may vary over time, it remains unclear how the pooling strategy's

performance evolves as the pandemic progresses.

We questioned to what extent optimal pooling strategies would have changed

throughout the COVID-19 pandemic and how testing facilities might use pooling

strategies for future testing in a correct and attainable manner. To this extent, we

simulated and evaluated one-dimensional (1D) and two-dimensional (2D) pooling

strategies with different pool sizes using real-life RT-qPCR data gathered by the

Belgian national testing platform during the end of the first and the beginning of the

second SARS-CoV-2 epidemiological waves. Additionally, we formulate a detailed

action plan to provide testing laboratories with the most suitable pooling strategy

assuring an optimal efficiency-sensitivity trade-off.

Materials and Methods

Patient samples

Nasopharyngeal swabs were taken by a healthcare professional as a diagnostic test

for SARS-CoV-2, as part of the Belgian national testing platform. The individuals

were tested at nursing homes or in triage centers, between April 9th and June 7th, and

between September 1st and November 10th. After filtering the data as described

further, this resulted in 207 944 patients in total, of which 9673 positives (4.65%).

SARS-CoV-2 RT-qPCR test

During the first (spring) wave, RNA extraction was performed using the Total RNA

Purification Kit (Norgen Biotek #24300) according to the manufacturer's instructions

using 200 µl transport medium, 200 µl lysis buffer and 200 µl ethanol, with

processing using a centrifuge (5810R with rotor A-4-81, both from Eppendorf). RNA

was eluted from the plates using 50 µl elution buffer (nuclease-free water), resulting

in approximately 45 µl eluate. RNA extractions were simultaneously performed for 94

patient samples and 2 negative controls (nuclease-free water). After addition of the

lysis buffer, 4 µl of a proprietary 700 nucleotides spike-in control RNA (prior to May

25th, 40 000 copies for singleplex RT-qPCR; from May 25th onwards, 5000 copies for

duplex RT-qPCR) and carrier RNA (200 ng of yeast tRNA, Roche #10109517001)

was added to all 96 wells from the plate. To the eluate of one of the negative control

wells, 7500 RNA copies of positive control RNA (Synthetic SARS-CoV-2 RNA

Control 2, Twist Biosciences #102024) were added. During the second (autumn)

wave, RNA extraction was performed using the Quick-RNA Viral 96 Kit (Zymo

Research #R1041), according to the manufacturer's instructions using 100 µl

transport medium, with processing using a centrifuge (5810R with rotor A-4-81, both

from Eppendorf). RNA was eluted from the plates using 30 µl elution buffer

(nuclease-free water). RNA extractions were simultaneously performed for 92 patient

samples, 2 negative controls (nuclease-free water), and 2 positive controls (1 diluted

positive case as a full workflow control; 1 positive control RNA as RT-qPCR control,

see further). After addition of the lysis buffer, 4 µl of a proprietary 700 nucleotides

spike-in control RNA (5000 copies) and carrier RNA (200 ng of yeast tRNA, Roche

#10109517001) was added to all 96 wells from the plate. To the eluate of one of the

negative control wells, 7500 RNA copies of positive control RNA (Synthetic SARS-

CoV-2 RNA Control 2, Twist Biosciences #102024) were added.

Six µl of RNA eluate was used as input for a 20 µl RT-qPCR reaction in a CFX384

qPCR instrument using 10 µl iTaq one-step RT-qPCR mastermix (Bio-Rad

#1725141) according to the manufacturer's instructions, using 250 nM final

concentration of primers and 400 nM of hydrolysis probe. Primers and probes were

synthesized by Integrated DNA Technologies using clean-room GMP production. For

detection of the SARS-CoV-2 virus, the Charité *E* gene assay was used (FAM)[15]; for

the internal control, a proprietary hydrolysis probe assay (HEX) was used. Prior to

May 25th, 2 singleplex assays were performed; from May 25th onwards, 1 duplex RT-

qPCR was performed. Cq values were generated using the FastFinder software

v3.300.5 (UgenTec). Only batches were approved with a clean negative control and

a positive control in the expected range.

Digital PCR calibration of positive control RNA

Digital PCR was done on a QX200 instrument (Bio-Rad) using the One-Step RT-

ddPCR Advanced Kit for Probes (Bio-Rad #1864022) according to the

manufacturer's instructions. Briefly, 22 μl pre-reactions were prepared consisting of 5

μl 4x supermix, 2 μl reverse transcriptase, 6 μl positive control RNA (125 RNA

copies/μl), 15 mM dithiothreitol, 900 nM of each forward and reverse primer and 250

nM *E* gene hydrolysis probe (FAM) (see higher). 20 μl of the pre-reaction was used

for droplet generation using the QX200 Droplet Generator, followed by careful

transfer to a 96-well PCR plate for thermocycling: 60 min 46 °C reverse transcription,

10 min 95 °C enzyme activation, 40 cycles of 30 sec denaturation at 95 °C and 1 min

annealing/extension at 59 °C, and finally 10 min 98 °C enzyme deactivation. Droplets

were analyzed by the QX200 Droplet Reader and QuantaSoft software. With an RNA

input of 7500 copies per reaction, the digital PCR result was 1500 cDNA copies (or

20% of the expected number, a fraction confirmed by Dr. Jim Huggett for particular

lot numbers of #102024, personal communication). The median Cq value of the

positive control RNA of 24.55 thus corresponds to 1500 digital PCR calibrated cDNA

molecules.

Determination of efficiency and sensitivity for simulated of 1D and 2D pooling

strategies

Simulations are run using R 4.0.1. First, several cohorts of 100 000 patients are

repeatedly simulated with varying fractions of positive cases f, depending on the

fraction of positive samples of the investigated week. This is done five times,

resulting in five replicate cohorts per week. The Cq values of the positive samples

are sampled with replacement from the set of the positive Cq values of said week.

Next, the patients are randomly separated into pools depending on the pooling

strategy that is simulated. The pooling strategies that were simulated are 1x4, 1x8,

1x12, 1x16, 1x24 (all 1D), and 8x12, 12x16 and 16x24. The Cq value of the pool was

calculated as follows:

$$c_{pool} = \log_2 P - \log_2 \sum_{i=1}^{p} 2^{-c_i} \quad \#(1)$$

With c_{pool} the Cq value of the pool, P the number of samples in the pool, p the

number of positive samples in the pool, $c_1, c_2, \ldots, c_p$ the Cq values of the positive

samples. If the Cq value of the pool is lower than the single-molecule Cq value, it is

classified as a positive pool. For 1D pooling, only samples in positive pools are

retained and the remaining individual Cq values were checked to be positive. For 2D

pooling, the Cq values of the differently sized pools are checked simultaneously and

the samples in negative pools are removed, after which all Cq values of the

remaining samples are checked individually. Samples that were retained after the

testing of the pools and that had an individual Cq lower than the single-molecule Cq

value are classified as positive, all other samples are classified as negative.

The sensitivity is calculated as:

$$sensitivity = \frac{no.\ true\ positive\ samples}{no.\ true\ positive\ samples + no.\ false\ negative\ samples} \#(2)$$

179   The analytical efficiency gain is calculated as:

$$efficiency\ gain = \frac{no.\ tests\ required\ for\ individual\ testing}{no.\ tests\ required\ for\ pooling\ strategy} \#(3)$$

In all simulations, the number of tests required for individual testing is equal to the

number of samples (assuming no technical failures). The outcomes for each

simulation were identical as the sample size far outreached the size of the dataset.

The code is available at https://github.com/OncoRNALab/covidpooling.

Ad hoc sensitivity and efficiency calculation

To calculate the efficiency for a specific 1D pooling strategy on a real sample set, the

following equation was used:

$$efficiency = \frac{n}{\frac{n}{s} \cdot \left(1 + s \cdot \sum_{k=1}^{s} \left(\frac{s!}{k!\,(s-k)!} \cdot p^k \cdot (1-p)^{s-k} \cdot (1-c^k)\right)\right)} \#(4)$$

192 With sample size n, pool size s, fraction of positive samples p and fraction of Cq

193 values of positive samples above the 'dilution detection limit': the lowest individual Cq

194 value that can result in a pooled Cq value lower than the single molecule Cq value,

195 or:

$$single\ molecule\ Cq\ value - log_2(pool\ size)\#(5)$$

197 Equation (4) is derived as follows. The efficiency is defined by the following equation:

$$efficiency = \frac{n}{no.\ tests\ required\ for\ pooling\ strategy} \#(6)$$

199 The number of tests performed when using a pooling strategy is equal to:

$$no.\ tests\ required\ for\ pooling\ strategy = no.\ pools + no.\ positive\ pools \cdot s\#(7)$$

201 Since $\# \, pools = \frac{n}{s}$,

$$no.\,tests\,required\,for\,pooling\,strategy = \frac{n}{s} + no.\,positive\,pools \cdot s \# (8)$$

202 The exact number of positive pools can be calculated by multiplying the number of
203 pools by the probability of a pool testing positive. Approximately, a pool will test
204 positive if it includes a positive sample with a Cq value lower than the 'dilution
205 detection limit'. The probability of having a specific number of positive samples k in a
206 pool with pool size s is defined by a binomial distribution:

$$\frac{s!}{k!\,(s-k)!} \cdot p^k \cdot (1-p)^{s-k} \# (8)$$

208 Thus, the probability of having at least one positive value in a pool is equal to:

$$\sum_{k=1}^{s} \left(\frac{s!}{k!\,(s-k)!} \cdot p^k \cdot (1-p)^{s-k} \right) \# (10)$$

210 In general, we can assume that when a sample has a Cq value higher than the
211 'dilution detection limit', for the sample to test positive, it must be accompanied by a
212 sample with a Cq value lower than the 'dilution detection limit'. Equation (10) can be
213 adjusted to factor for these events:

$$\sum_{k=1}^{s} \left(\frac{s!}{k!\,(s-k)!} \cdot p^k \cdot (1-p)^{s-k} \cdot (1-c^k) \right) \# (10)$$

215 Filling in Eq. (10) in Eq. (8) results in the final formula being used for the calculation
216 of the efficiency.

218   To estimate the sensitivity for a specific 1D pooling strategy on a real sample set, the

219   following equation was used:

$$sensitivity = c \cdot \sum_{k=0}^{s-1} \left(\frac{(s-1)!}{k!\left((s-1)-k\right)!} \cdot p^k \cdot (1-p)^{(s-1)-k} \cdot (1-c^k) \right) + (1-c) \quad \#(11)$$

221   The sensitivity can be defined as the probability a true positive sample tests positive.

222   For our situation it will be equal to the probability that any sample tests positive:

$$P(pos\ test) = P(pos\ test|Cq \geq cut\ off) \cdot P(Cq \geq cut\ off) +$$
$$P(pos\ test|Cq < cut\ off) \cdot P(Cq < cut\ off) \quad \#(12)$$

Previously, $P(Cq \geq cut\ off)$ was defined as c and therefore $P(Cq < cut\ off) = 1 - c$.

Also $P(pos\ test|Cq < cut\ off) = 1$. A positive sample with Cq value above the

'dilution detection limit' can only test positive if one of the other samples in the pool is

also positive and has a Cq value lower than the 'dilution detection limit'. We can

calculate the probability of this happening by using the same logic as before, but with

$s - 1$ instead of s:

$$\sum_{k=0}^{s-1} \left(\frac{(s-1)!}{k!\left((s-1)-k\right)!} \cdot p^k \cdot (1-p)^{(s-1)-k} \cdot (1-c^k) \right) \quad \#(13)$$

Completing Eq. (12) with Eq. (13) leads to Eq. (11) for calculating the sensitivity.

Shiny application

To help laboratories find the best pooling strategy for their specific situation (i.e. the

local positivity ratio and Cq value distribution), we developed a Shiny application in R

4.0.1. The Shiny application was launched on our in-house Shiny server and is

available at https://shiny.dev.cmgg.be/.

Results

Single-molecule Cq value determination

We made a 5-point 10-fold serial dilution series of positive control RNA from 150 000

(digital PCR calibrated) copies down to 15 copies. The Y-intercept value points at a

single-molecule Cq value of 35.66 and 35.28 for singleplex and duplex RT-qPCR,

respectively (Supplemental Figure 1). Therefore, we conservatively use 37 as the

single-molecule value for further analysis. Patient sample Cq values higher than the

single-molecule Cq value threshold are likely due to random measurement variation,

lot reagent variability and sample inhibition.

Cq distribution is dynamic over course of the pandemic

Few studies have explored how the Cq value distribution within one testing facility

evolves during the COVID-19 pandemic. We determined the 75%-tile of the Cq value

distribution and the percentage of positive tests per day as a proxy for actual Cq

value distribution and prevalence, respectively (Figure 2). We compared the fraction

of positive tests in our dataset with the fraction of positive tests as reported by the

federal agency for public health Sciensano (https://epistat.wiv-isp.be/covid/.

accessed January 25th, 2021). First, the fractions of positive tests seem to align at

the end of the first wave, but in the second wave our data seems to be shifted about

one to two weeks later. Second, the 75%-tile of the Cq values varies over the course

of the pandemic from a minimum value of around 18 and a maximum value of almost

35. Third, when comparing the fraction of positive samples and the 75%-tile of the Cq

value distribution, we note that these parameters are inversely related: when the

positivity rate goes down, the Cq value distribution shifts towards the higher end of

the spectrum. In conclusion, the Cq value distribution and prevalence show a

dynamic profile over the course of the COVID-19 pandemic. These observations are

crucial considering that positivity rate and Cq value distribution are key determinants

of efficiency and sensitivity of any pooling strategy.

Pooling efficiency and sensitivity changes as pandemic progresses

To explore how hypothetical pooling strategies would have affected the SARS-CoV-2

testing outcomes, we simulated different 1D (with pool size of 4, 8, 12, 16 and 24)

and 2D pooling (with pool sizes of 8x12, 12x16, and 16x24) strategies using

individual sample Cq values from a single Belgian laboratory during the end of the

first and beginning of the second wave. The data was grouped by week and the

resulting Cq value distributions and positivity rates were used as input for the

simulations (Figure 3). First, sensitivity and efficiency show very opposing patterns

when comparing different timeframes during the pandemic. At the end of the first

wave the efficiency increases, while at the beginning of the second wave, the

efficiency decreases. The sensitivity drops as we move further away from the first

wave but remains stable as we enter the second. Second, pool size and strategy

have a major influence on the outcomes. 2D pooling strategies generally have the

highest efficiency, but the lowest sensitivity. Curiously, strategies with larger pool

sizes were more efficient during the end of the first wave, but less efficient during the

beginning of the second wave. The sensitivity was always higher for strategies with

smaller pool sizes, irrespective of the time during the pandemic. We conclude that—

just like the positivity rate and the Cq value distribution—the sensitivity and efficiency

depend on the timing in the pandemic and are heavily affected by the pooling

strategy and the size of the pools.

Positivity rate drives efficiency, Cq distribution drives sensitivity

We wondered how the positivity rate, Cq value distribution and pooling strategy affect

the performance of the adopted strategy. To investigate this, we used the previous

simulations for the end of the first wave to create an adjusted visualization where all

parameters involved are incorporated (Figure 4). First, it is apparent that weeks with

a high 75%-tile Cq value tend to have a low sensitivity and weeks with a high

positivity rate seem to have a low efficiency. Second, pooling strategies with smaller

pool sizes seem less sensitive to changes in positivity rate and Cq value distribution,

as indicated by the area of the polygon traced around the edges of the data (Figure

4). These results show that the prevalence mainly contributes to the efficiency and

the Cq distribution to the sensitivity.

Shiny app for guided decision making

To provide laboratories with a custom pooling strategy recommendation based on

their specific sampling population, we worked out equations to estimate the

sensitivity and efficiency (for 1D pooling strategies) based on an uploaded dataset of

Cq values. The derivation of these equations can be found in the Methods section.

We focused on 1D pooling strategies since 2D pooling strategies generally resulted

in extreme outcomes (highest efficiency and lowest sensitivity) and the outcomes of

the optimal pooling strategy are situated somewhere in two extremes. To evaluate

the equations' capacities to replicate the simulations, we compared the simulated

efficiency and sensitivity of the pooling strategies for the different weeks and the

efficiency and sensitivity of the pooling strategies the distributions, fraction of positive

samples and single-molecule cutoff as inputs for the formulas (Supplemental Figure

2 and Supplemental Figure 3). We integrated these formulas into an open-access

Shiny application (Supplemental Figure 4). The application requires three inputs: a

dataset of Cq values from positive samples, the positivity rate and the single-

molecule cut-off Cq value. The Shiny application will then swiftly output the estimated

data-specific efficiency and sensitivity for different pooling strategies.

320 **Discussion**

Using a sizeable real-life dataset of 9673 SARS-CoV-2 positive nasopharyngeal

samples, we found that the pooling strategies' sensitivity and efficiency mainly

depend on the prevalence and the distribution of the Cq values. Our results indicate

that both the prevalence and the Cq value distribution are dynamic parameters

during the SARS-CoV-2 pandemic and that, as a result, the resulting sensitivity and

efficiency of pooling strategies are as well. To enable researchers and institutions

with a real-time and accessible recommendation concerning the optimal 1D pooling

strategy for their testing population, we developed a Shiny app providing just that.

Two factors could explain the dynamics of the prevalence and the Cq value

distribution: epidemiological and virological change within the same sampling

population and variation in the sampling population. The existence of these factors

would suggest that an intricate interplay of these two components is at the origin of

the observed evolutions. Recent research indicated that the first component

(epidemiological change) exists, as the distribution of random surveillance testing-

deduced Cq values fluctuates during the SARS-CoV-2 pandemic (by definition, no

changes in sampling population occurred in this research, thereby excluding this

factor from the equation)[16]. The second component (variation in sampling population)

is bound to happen when the testing facility is not consistently receiving samples

from the same origin, as is the case for Biogazelle. At the very introduction of

Biogazelle as a testing facility, most samples originated from hospitals and sources

were added progressively as the testing capacity increased. Additionally, the Belgian

government instituted a rapid change in the testing regime on October 21st, 2020:

only symptomatic suspected SARS-CoV-2 cases get tested. The federal government

lifted this measure on November 23rd, 2020, when the number of cases lowered and

the existing testing capacity sufficed again. Since symptomatic patients generally

show lower Cq values[17,18], it is clear that sampling bias will contribute to the overall

Cq value distribution.

The influence these dynamic parameters have on the variation of performance of

pooling strategies is significant. This observation raises an issue for interpreting

pooling strategy evaluations not based on time-series datasets. The effectiveness of

a chosen pooling plan might even decrease to such an extent that it becomes inferior

to individual testing. We observed this situation at the end of the second wave when

efficiency is close to 1, but sensitivity is not (Figure 3). Based on these results, it

becomes essential to regularly re-evaluate an adopted pooling strategy to avoid

compromising on sensitivity and efficiency when there is no need.

Multiple effects contribute to how the testing population's characteristics drive pooling

strategy outcomes. The main trends show that the prevalence mainly influences

efficiency, and the Cq value distribution mainly influences sensitivity (Figure 3). We

can explain both observations by using common sense and basic mathematics.

When the prevalence is low, the efficiency is high: fewer pools will have positive

samples and therefore test negative, which will automatically result in a lower number

of tests needed to test all samples. Additionally, when a considerable proportion of

samples have a Cq value close to the single-molecule Cq value, a more significant

fraction of samples will become too diluted to detect during pooling and result in false

negatives. There appear to be secondary compensating effects of the Cq value

distribution and prevalence on the efficiency and sensitivity, respectively, which are

more subtle. Primarily, as a higher fraction of positive samples has a Cq value close

to the upper limit, more pools will test (false) negative, boosting the efficiency. On the

other hand, when the prevalence increases, the sensitivity will increase due to an

effect we call 'rescuing': a high Cq value that would otherwise test negative when

diluted in the pool is 'rescued' by a low Cq value in the same pool. When the

prevalence rises, the chances of this phenomenon happening also increase and as

will the sensitivity. The same was observed by Cleary et al.[19]. Although minor, these

secondary effects explain a number of our observations.

To elaborate how the optimal pooling strategy (best efficiency trade-off) transforms

over time, assume two situations: low prevalence and high prevalence. When the

prevalence is low, the larger pool sizes will result in higher efficiency and lower

prevalence (more dilution). However, when the prevalence is high, the 'rescuing'

effect will be more prominent and counteract the increasing efficiency and decreasing

sensitivity. These results are in line with the widely accepted idea that sample pooling

methods show a higher efficiency when pool size is large and that as prevalence

increases, it reached a threshold after which smaller pool sizes become more

efficient[1,9]. Intuitively, the 'rescuing' effect is less prominent in 2D pooling strategies,

as both pools (row and column) need to rescue the high Cq sample.

False negatives have pre-pool Cq values close to the detection limit and

predominantly originate from patients who are at the end of an infection[19,20], putting

their clinical relevance in question (i.e. no longer infectious). Similarly, however, one

can argue that these high Cq samples are imperative to a favorable pandemic

response: they might originate from pre-symptomatic or very recently-infected

patients[19], allowing for catching cases before transmission—a principle at the very

core of every population screening strategy. Also, we cannot rule out that these high

Cq values are due to imperfect sampling or any other mistakes along the sample

preparation[13].

Our study suffers from some essential limitations. First, although the data grouped by

weeks provides many different situations to assess, there will still be other

combinations of parameters that we did not analyze in this paper. However, the

current dataset probably represents the most plausible scenarios as the data

originates from a protracted period of the pandemic. Second, we selected only 1D

and 2D pooling methods in this simulation study. As stated before, other pooling

regimes exist and might be more performant than the discussed ones. Yet, these

pooling strategies come with intrinsic shortcomings. The P-BEST pooling protocol is

very time consuming[10], even when using a pipetting robot, and the repeated pooling

method suffers from a complicated re-pooling scheme[1]. Third, our model relies on

the critical assumption that we can directly induce the pool's Cq value from the

individual samples' Cq values using a simple formula (see Methods). Wet lab

experiments have shown that this is not necessarily the case[5–8]. Fourth, to calculate

the pooling strategies' performance, the single-molecule Cq value and the

prevalence must be known. However, we can easily calculate the single-molecule Cq

value by generating a ddPCR calibrated dilution series as done in this paper. The

prevalence, however, cannot be known precisely, and as a result, the prevalence

must be estimated. We can do this either before adopting a pooling strategy by

testing the individual samples and using the fraction of positive samples as an

indication for the prevalence or when a pooling strategy is already in place by

calculating it from the percentage of positive pools[2,19]. Last, the calculated efficiency

gain is merely a representation of the number of individual RNA extractions and RT-

qPCR reactions and does not evaluate the amount of labor or time-to-result. Pooling

a low number of samples will unnecessarily increase the time-to-result and workload.

In conclusion, we show that finding the optimal pooling strategy for SARS-CoV-2 test

samples is guided by a testing population-dependent efficiency-sensitivity trade-off.

Consequently, the most favorable pooling regime might change throughout the

pandemic due to epidemiological changes and revisions in diagnostic testing

strategies. We provide an accessible shiny application to guide readers towards the

optimal pooling strategy to fit their needs.

425 Acknowledgements

We are grateful for the data from the Belgian federal taskforce for COVID-19 qPCR

testing.

Conceptualization: J.Va., P.M. and J.Ve.; Methodology: J.Va., P.M. and J.Ve.;

Software: J.Ve., T.S.; Formal Analysis: J.Ve.; Resources: J.H., J.Va. and P.M.; Data

Curation: J.Ve.; Writing – Original Draft: J.Va. and J.Ve.; Writing – Review & Editing;

J.Va., J.H., P.M., T.S. and J.Ve.; Visualisation: J.Va. and J.Ve.; Supervision: J.Va

and P.M.; Project Administration: J.Va. and P.M.

435 Data availability

436 The code and Cq values are available on

437 https://github.com/OncoRNALab/covidpooling.

References

1. Shani-Narkiss H, Gilday OD, Yayon N, Landau ID. Efficient and Practical Sample Pooling High-Throughput PCR Diagnosis of COVID-19. MedRxiv, 2020:2020.04.06.20052159

2. Guha P, Guha A, Bandyopadhyay T. Application of pooled testing in screening and estimating the prevalence of Covid-19. MedRxiv, 2020:2020.05.26.20113696

3. Adams K. Expanding Covid-19 Testing: Mathematical Guidelines for the Optimal Sample Pool Size Given Positive Test Rate. MedRxiv, 2020:2020.05.21.20108522

4. Millioni R, Mortarino C. Sequential informed pooling approach to detect SARS-CoV2 infection. MedRxiv, 2020:2020.04.24.20077966

5. Hogan CA, Sahoo MK, Pinsky BA. Sample Pooling as a Strategy to Detect Community Transmission of SARS-CoV-2. JAMA - J Am Med Assoc, 2020, 323:1967–9

6. Yelin I, Aharony N, Shaer Tamar E, Argoetti A, Messer E, Berenbaum D, Shafran E, Kuzli A, Gandali N, Shkedi O, Hashimshony T, Mandel-Gutfreund Y, Halberthal M, Geffen Y, Szwarcwort-Cohen M, Kishony R, Taub Professor H. Evaluation of COVID-19 RT-qPCR test in multi-sample pools. Clin Infect Dis, 2020. https://doi.org/https://doi.org/10.1093/cid/ciaa531

7. Abdalhamid B, Bilder CR, McCutchen EL, Hinrichs SH, Koepsell SA, Iwen PC. Assessment of Specimen Pooling to Conserve SARS CoV-2 Testing Resources. Am J Clin Pathol, 2020, 153:715–8

8. Torres I, Albert E, Navarro D. Pooling of nasopharyngeal swab specimens for SARS-CoV-2 detection by RT-PCR. J Med Virol, 2020, 92:2306–7

9.   Sinnott-Armstrong N, Klein D, Hickey B. Evaluation of Group Testing for SARS-

CoV-2 RNA. MedRxiv, 2020:2020.03.27.20043968

10.   Shental N, Levy S, Wuvshet V, Skorniakov S, Shalem B, Ottolenghi A,

Greenshpan Y, Steinberg R, Edri A, Gillis R, Goldhirsh M, Moscovici K,

Sachren S, Friedman LM, Nesher L, Shemer-Avni Y, Porgador A, Hertz T.

Efficient high-throughput SARS-CoV-2 testing to detect asymptomatic carriers.

Sci Adv, 2020, 6:5961–72

11.   Ghosh S, Agarwal R, Rehan MA, Pathak S, Agrawal P, Gupta Y, Consul S,

Gupta N, Goyal R, Rajwade A, Gopalkrishnan M. A Compressed Sensing

Approach to Group-testing for COVID-19 Detection. ArXiv, 2020

12.   Gan Y, Du L, Damola FO, Huang J, Xiao G, Lyu X. Sample Pooling as a

Strategy of SARS-COV-2 Nucleic Acid Screening Increases the False-negative

Rate. MedRxiv, 2020:2020.05.18.20106138

13.   Dahdouh E, Lázaro-Perona F, Romero-Gómez MP, Mingorance J, García-

Rodriguez J. Ct values from SARS-CoV-2 diagnostic PCR assays should not

be used as direct estimates of viral load. J Infect, 2020.

https://doi.org/10.1016/j.jinf.2020.10.017

14.   Buchan BW, Hoff JS, Gmehlin CG, Perez A, Faron ML, Munoz-Price LS,

Ledeboer NA. Distribution of SARS-CoV-2 PCR cycle threshold values provide

practical insight into overall and target-Specific sensitivity among symptomatic

patients. Am J Clin Pathol, 2020. https://doi.org/10.1093/AJCP/AQAA133

15.   Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T,

Brünink S, Schneider J, Schm ML, Mulders DG, Haagmans BL, van der Veer

B, van den Brink S, Wijsman L, Goderski G, Romette J-L, Ellis J, Zambon M,

Peiris M, Goossens H, Reusken C, Koopmans MP, Drosten C. Detection of

2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance,

2020, 25:2000045

16.   Hay JA, Kennedy-Shaffer L, Kanjilal S, Lipsitch M, Mina MJ. Estimating

epidemiologic dynamics from single cross-sectional viral load distributions.

MedRxiv, 2020:2020.10.08.20204222

17.   Singanayagam A, Patel M, Charlett A, Bernal JL, Saliba V, Ellis J, Ladhani S,

Zambon M, Gopal R. Duration of infectiousness and correlation with RT-PCR

cycle threshold values in cases of COVID-19, England, January to May 2020.

Eurosurveillance, 2020. https://doi.org/10.2807/1560-

7917.ES.2020.25.32.2001483

18.   Gorzalski AJ, Hartley P, Laverdure C, Kerwin H, Tillett R, Verma S, Rossetto

C, Morzunov S, Hooser S Van, Pandori MW. Characteristics of viral specimens

collected from asymptomatic and fatal cases of COVID-19. J Biomed Res,

2020, 34:431–6

19.   Cleary B, Hay JA, Blumenstiel B, Harden M, Cipicchio M, Bezney J, Simonton

B, Hong D, Senghore M, Sesay AK, Gabriel S, Regev A, Mina MJ. Using viral

load and epidemic dynamics to optimize pooled testing in resource-constrained

settings. Sci Transl Med, 2021:eabf1568

20.   Tom MR, Mina MJ. To Interpret the SARS-CoV-2 Test, Consider the Cycle

Threshold Value. Clin Infect Dis, 2020, 71:2252–4

Figures

Figure 1

Figure 2

Figure 3

Figure 4

Figure Legends

Figure 1: Schematic overview of the applied pooling strategies. The samples are represented as wells

in a 96-well microtiter plate. The color of the wells indicates the samples' SARS-CoV-2 RNA

concentration. In 1D pooling, the pools are created by row, the pools are tested and the samples in

positive pools are tested again individually. During 2D pooling, the pools are created by row and

column (each sample exists in two pools), the pools are tested, all negative rows and columns are

removed and the remaining samples are tested individually. The sensitivity and the efficiency are

calculated according to the equations found in the methods.

Figure 2: Evolution of the 75%-tile of the Cq value distribution and fraction of positive samples. The

left y-axis shows the seven day moving window average of the 75%-tile of the Cq value distribution of

the data originating from Biogazelle and the right y-axis shows the seven day moving window average

of the fraction of positive samples for the Biogazelle and Sciensano data. The two datasets are

differentiated by the line type. If the moving average was calculated using on the basis of less than

five days (due to no data being available for specific days), the datapoint was removed from the

visualization.

Figure 3: Sensitivity and efficiency for the end of the first (A) and the start of the second (B) Belgian

SARS-CoV-2 infection wave. The data is grouped by week and the sensitivity and efficiency are

calculated by simulating different pooling strategies (1x4, 1x8, 1x12, 1x16, 1x24, 8x12, 12x16 and

16x24). The pooling strategies can be distinguished by color.

Figure 4: Simulated sensitivity and efficiency for the end of the first wave visualized with relation to

the week (different circles), fraction of positive samples (size of circles) and 75%-tile of the Cq value

distribution (color). A polygon is drawn around the datapoints (with a small margin) to visualize and to

compare the variability of the sensitivity and efficiency over a period of time between pooling

strategies.

Supplemental Information to *Evaluation of efficiency and sensitivity*

of 1D and 2D sample pooling strategies for SARS-CoV-2 RT-qPCR

screening purposes

Jasper Verwilt[1,2,3], Jan Hellemans[4], Tom Sante[2,3], Pieter Mestdagh[1,2,3,4], Jo Vandesompele[1,2,3,4]

1 OncoRNALab, Cancer Research Institute Ghent, Corneel Heymanslaan 10, 9000 Ghent, Belgium

2 Department of Biomolecular Medicine, Ghent University, Corneel Heymanslaan 10, 9000 Ghent, Belgium

3 Center for Medical Genetics, Ghent University, Corneel Heymanslaan 10, 9000 Ghent, Belgium

4 Biogazelle, Technologiepark-Zwijnaarde 82, 9052 Gent, Belgium

- 4 supplemental figures

575 **Supplemental Figures**

578 **Supplemental Figure 1:** Sensitivity analysis of singleplex and duplex qPCR assays using

579 predetermined number of cDNA molecules. R-squared values are adjusted using the Wherry formula.

580 Each number of cDNA molecules was tested in triplicate.

Supplemental Figure 2: Concordance of sensitivity estimations between simulations and calculations for the end of the first Belgian SARS-CoV-2 infection wave. The numbers represent the weeks (1: 1st week; 2: 2nd week; …) and are plotted at the sensitivities derived from the simulations and calculations. The red line represents the points where both values are equal.

Supplemental Figure 3: Concordance of efficiency estimations between simulations and calculations

for the end of the first Belgian SARS-CoV-2 infection wave. The numbers represent the weeks (1: 1st

week; 2: 2nd week; …) and are plotted at the efficiencies derived from the simulations and calculations.

The red line represents the points where both values are equal.

Supplemental Figure 4: A screenshot of the interface of the Shiny application. The webpage

provides the user with a short description and a detailed outline of how to use the application. In the

upper left corner, the user can provide their dataset. If the user would prefer to first explore the app

without using their own data, a demo dataset can be downloaded and used instead. The user can fill

in the estimated prevalence and single-molecule Cq value. The slider underneath can be used to

indicated which range of pool sizes the user wishes to explore. Upon uploading the data, a graph will

be outputted in the "Plot" tab, showing the estimated sensitivity and efficiency of each pool size. The

vertical dashed lines represent the pool size at which the corresponding parameter reaches its

maximal value for this data. The "Data" tab provides the user with a tabulated overview of the

estimated sensitivity and efficiency of each pool size.

1D pooling

1D pooling

sensitivity: 66.7% (4/6)
efficiency: 2.2x (96/44)

2D pooling

2D pooling

sensitivity: 50% (3/6)
efficiency: 3.2x (96/29)

retain
positive
pools

test
remainder
individually

negative sample

high Cq value positive

low Cq value positive

Upload dataset

Browse...	demo_dataset_Cq_values.csv
Upload complete	

 Download demo dataset

Prevalence in %:

Cq threshold:

Pool size range:

2 ——————————————— 24

2   5   8   11   14   17   20   23 24

Estimate sensitivity and efficiency of a 1D sample pooling strategy (version 1.0)

This application calculates the sensitivity and efficiency for 1D pooling strategies from custom uploaded RT-qPCR data (Cq values). The efficiency is the number of samples deivided by the number of tests required. The sensitivity is the number of true positives (upon pooling and retesting individuals from positive pools) divided by the actual number of positives. This application is based on the results from "Evaluation of efficiency and sensitivity of 1D and 2D sample pooling strategies for diagnostic screening purposes" by Verwilt et al. (under review). In case you have any questions, please contact jasper.verwilt@ugent.be.

How to use the app

1. Upload your dataset with Cq values from positive samples in .csv format. Use a point as decimal separator.

2. Fill in your estimated prevalence.

3. Fill in your single-molecule Cq value (i.e. Cq value corresponding to a single cDNA molecule; alternatively, the Cq value threshold above which you consider a sample negative).

4. Use the slider to indicate the range of pool sizes you would like to explore

You can download the demo dataset to examine what the data should look like. A new graph will automatically be generated once one of the input values changes. The efficiency is shown in black and the sensitivity is shown in green. Vertical dashed lines indicate the pool size for which the efficiency and sensitivity reach their maximal value.

Plot   Data   FAQ